<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">7951</article-id><article-id pub-id-type="doi">10.36691/RJA7951</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original studies</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Clinical predictors of antihistamine resistance in patients with chronic spontaneous urticaria</article-title><trans-title-group xml:lang="ru"><trans-title>Клинические предикторы резистентности к антигистаминным препаратам у пациентов с хронической спонтанной крапивницей</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7855-6207</contrib-id><contrib-id contrib-id-type="spin">5794-9317</contrib-id><name-alternatives><name xml:lang="en"><surname>Popova</surname><given-names>Christina Yu.</given-names></name><name xml:lang="ru"><surname>Попова</surname><given-names>Кристина Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>popova.derm@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5044-1152</contrib-id><contrib-id contrib-id-type="spin">5969-8486</contrib-id><name-alternatives><name xml:lang="en"><surname>Zaborova</surname><given-names>Victoria A.</given-names></name><name xml:lang="ru"><surname>Заборова</surname><given-names>Виктория Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>vaz111v@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1729-0513</contrib-id><contrib-id contrib-id-type="spin">2766-3925</contrib-id><name-alternatives><name xml:lang="en"><surname>Kurshev</surname><given-names>Vladislav V.</given-names></name><name xml:lang="ru"><surname>Куршев</surname><given-names>Владислав Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>kurshevvlad@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1212-3767</contrib-id><contrib-id contrib-id-type="spin">3078-0976</contrib-id><name-alternatives><name xml:lang="en"><surname>Kovalkova</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Ковалькова</surname><given-names>Елена Вячеславовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>kovalkova@ya.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8472-1152</contrib-id><contrib-id contrib-id-type="spin">6644-6715</contrib-id><name-alternatives><name xml:lang="en"><surname>Serdotetskova</surname><given-names>Sofia A.</given-names></name><name xml:lang="ru"><surname>Сердотецкова</surname><given-names>Софья Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>darklynx813@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5083-6637</contrib-id><contrib-id contrib-id-type="spin">3023-4538</contrib-id><name-alternatives><name xml:lang="en"><surname>Fomina</surname><given-names>Daria S.</given-names></name><name xml:lang="ru"><surname>Фомина</surname><given-names>Дарья Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>daria_fomina@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1587-9137</contrib-id><contrib-id contrib-id-type="spin">4779-7664</contrib-id><name-alternatives><name xml:lang="en"><surname>Borzova</surname><given-names>Elena Yu.</given-names></name><name xml:lang="ru"><surname>Борзова</surname><given-names>Елена Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>eborzova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">The First Sechenov Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Moscow City Hospital 52, Moscow City Scientific and Practical Centre of Allergology and Immunology</institution></aff><aff><institution xml:lang="ru">Московский городской научно-практический центр аллергологии и иммунологии ГБУЗ «Городская клиническая больница № 52»</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-12-21" publication-format="electronic"><day>21</day><month>12</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-12-02" publication-format="electronic"><day>02</day><month>12</month><year>2023</year></pub-date><volume>20</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>402</fpage><lpage>414</lpage><history><date date-type="received" iso-8601-date="2023-04-29"><day>29</day><month>04</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-11-28"><day>28</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Фармарус Принт Медиа</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2026-02-02"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/7951">https://rusalljournal.ru/raj/article/view/7951</self-uri><abstract xml:lang="en"><p><bold><italic>BACKGROUND: </italic></bold>Сhronic spontaneous urticaria is characterized by itchy wheals and/or angioedema on the skin for ≥6 weeks. A large-scale international AWARE study by Russian researchers indicated the ineffectiveness of therapy with standard doses of second-generation antihistamines in &gt;50% of patients with chronic spontaneous urticaria. Clinical predictors of antihistamine resistance include low quality of life based on CU-Q2oL, baseline urticaria activity score for 7 days (UAS7) &gt;16, combination with chronic inducible urticaria, and autoimmune comorbidity. Currently, research into the clinical predictors of antihistamine resistance, including body mass index, in patients with chronic spontaneous urticaria is ongoing.</p> <p><bold><italic>AIM:</italic></bold><italic> </italic>To examine the degree of symptom control based on body mass index and physical activity in patients with chronic spontaneous urticaria treated with second-generation antihistamines.</p> <p><bold><italic>MATERIALS AND METHODS: </italic></bold>The examination of patients with сhronic spontaneous urticaria (<italic>n</italic>=34) included the clinical history and use of the following international questionnaires: UAS7, urticaria control test, dermatology quality of life index, and global physical activity questionnaire of the World Health Organization. The questionnaires were analyzed in subgroups of patients with controlled and uncontrolled chronic spontaneous urticaria and subgroups of patients with chronic spontaneous urticaria having normal weight, overweight, and obesity.</p> <p><bold><italic>RESULTS:</italic></bold><italic> </italic>Uncontrolled symptoms were observed in 24 (70.6%) patients with chronic spontaneous urticaria, including 11 (45.8%) with resistance to fourfold doses of second-generation antihistamines. In 52.9% of patients with chronic spontaneous urticaria, the body mass index exceeded normal values. In this study, an inverse correlation was found between the body mass index and the degree of control of chronic spontaneous urticaria symptoms.</p> <p><bold><italic>CONCLUSIONS: </italic></bold>Owing to the negative correlation between body mass index and the degree of symptom control, further research into the role of body mass index as a clinical predictor of antihistamine-resistant chronic spontaneous urticaria is needed. In the future, personalized therapy for chronic spontaneous urticaria may consider the degree of disease control, clinical predictors of antihistamine resistance, and proinflammatory biomarkers.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Хроническая спонтанная крапивница ― заболевание, характеризуемое спонтанным возникновением на коже зудящих волдырей и/или ангиоотёков на протяжении более 6 недель. Согласно данным международного исследования, терапия стандартными дозами антигистаминных препаратов второго поколения неэффективна более чем у 50% пациентов с хронической спонтанной крапивницей. К клиническим предикторам резистентности к антигистаминным препаратам относят низкие показатели качества жизни по данным опросника CU-Q2oL и UAS7 с исходным баллом &gt;16, а также сочетание с хроническими индуцированными крапивницами и наличие коморбидных аутоиммунных заболеваний.</p> <p><bold>Цель</bold> — изучить степень контроля симптомов заболевания в зависимости от индекса массы тела и уровня физической нагрузки у пациентов с хронической спонтанной крапивницей, получающих терапию антигистаминными препаратами второго поколения.</p> <p><bold>Материалы и методы.</bold> Обследование пациентов (<italic>n</italic>=34) с хронической спонтанной крапивницей включало сбор анамнеза и анкетирование с помощью международных опросников UAS7, UCT, DLQI, GPAQ. Анализ опросников осуществлялся в подгруппах пациентов с контролируемыми и неконтролируемыми симптомами хронической спонтанной крапивницы, а также в подгруппах пациентов с нормальной и избыточной массой тела и ожирением.</p> <p><bold>Результаты.</bold> Неконтролируемое течение заболевания отмечалось у 24 (70,6%) пациентов, из них у 11 (45,8%) наблюдалась резистентность к четырёхкратной дозе антигистаминных препаратов второго поколения. У 52,9% пациентов с хронической спонтанной крапивницей индекс массы тела превышал нормальные значения. В исследовании установлена обратная взаимосвязь индекса массы тела и степени контроля симптомов хронической спонтанной крапивницы.</p> <p><bold>Заключение.</bold> В связи с полученной отрицательной корреляцией между индексом массы тела и степенью контроля хронической спонтанной крапивницы роль индекса массы тела как клинического предиктора хронической спонтанной крапивницы, резистентной к антигистаминным препаратам, требует изучения. В перспективе персонализация терапии хронической спонтанной крапивницы может быть основана на степени контроля заболевания с учётом клинических предикторов резистентности к антигистаминным препаратам и биомаркеров воспаления.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic spontaneous urticaria</kwd><kwd>quality of life</kwd><kwd>resistance</kwd><kwd>body mass index</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая спонтанная крапивница</kwd><kwd>качество жизни</kwd><kwd>предикторы</kwd><kwd>антигистаминные препараты</kwd><kwd>индекс массы тела</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. doi: 10.1111/all.15090</mixed-citation><mixed-citation xml:lang="ru">Zuberbier T., Abdul Latiff A.H., Abuzakouk M., et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria // Allergy. 2022. Vol. 77, N 3. P. 734–766. doi: 10.1111/all.15090</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Allergology. Federal clinical recommendations. Ed. by R.M. Khaitov, N.I. Ilyina. Moscow: Pharmarus Print Media; 2014. 126 р. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Аллергология. Федеральные клинические рекомендации / под ред. Р.М. Хаитова, Н.И. Ильиной. Москва: Фармарус Принт Медиа, 2014. 126 с.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Moestrup K, Ghazanfar MN, Thomsen SF. Patient-reported outcomes (PROs) in chronic urticaria. Int J Dermatol. 2017;56(12):1342–1348. doi: 10.1111/ijd.13668</mixed-citation><mixed-citation xml:lang="ru">Moestrup K., Ghazanfar M.N., Thomsen S.F. Patient-reported outcomes (PROs) in chronic urticaria // Int J Dermatol. 2017. Vol. 56, N 12. P. 1342–1348. doi: 10.1111/ijd.13668</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011;66(3):317–330. doi: 10.1111/j.1398-9995.2010.02496.x</mixed-citation><mixed-citation xml:lang="ru">Maurer M., Weller K., Bindslev-Jensen C., et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report // Allergy. 2011. Vol. 66, N 3. P. 317–330. doi: 10.1111/j.1398-9995.2010.02496.x</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226–236. doi: 10.1111/bjd.19561</mixed-citation><mixed-citation xml:lang="ru">Gonçalo M., Gimenéz-Arnau A., Al-Ahmad M., et al. The global burden of chronic urticaria for the patient and society // Br J Dermatol. 2021. Vol. 184, N 2. P. 226–236. doi: 10.1111/bjd.19561</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc. 2006;27(2):96–99.</mixed-citation><mixed-citation xml:lang="ru">Weldon D.R. Quality of life in patients with urticaria // Allergy Asthma Proc. 2006. Vol. 27, N 2. P. 96–99.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197–201.</mixed-citation><mixed-citation xml:lang="ru">O'Donnell B.F., Lawlor F., Simpson J., et al. The impact of chronic urticaria on the quality of life // Br J Dermatol. 1997. Vol. 136, N 2. P. 197–201.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. doi: 10.1111/all.13397</mixed-citation><mixed-citation xml:lang="ru">Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria // Allergy. 2018. Vol. 73, N 7. P. 1393–1414. doi: 10.1111/all.13397</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Grob J, Auquier P, Dreyfus I, Ortonne J. How to prescribe antihistamines for chronic idiopathic urticaria: Desloratadine daily vs PRN and quality of life. Allergy. 2009;(64):605–612. doi: 10.1111/j.1398-9995.2008.01913.x</mixed-citation><mixed-citation xml:lang="ru">Grob J., Auquier P., Dreyfus I., Ortonne J. How to prescribe antihistamines for chronic idiopathic urticaria: Desloratadine daily vs PRN and quality of life // Allergy. 2009. Vol. 64. P. 605–612. doi: 10.1111/j.1398-9995.2008.01913.x</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Maurer M, Costa C, Gimenez Arnau A, et al. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. Clin Exp Allergy. 2020;50(10):1166–1175. doi: 10.1111/cea.13716</mixed-citation><mixed-citation xml:lang="ru">Maurer M., Costa C., Gimenez Arnau A., et al. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study // Clin Exp Allergy. 2020. Vol. 50, N 10. P. 1166–1175. doi: 10.1111/cea.13716</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: A systematic review and meta-analysis. Br J Dermatol. 2016;175(6):1153–1165. doi: 10.1111/bjd.14768</mixed-citation><mixed-citation xml:lang="ru">Guillen-Aguinaga S., Jauregui Presa I., Aguinaga-Ontoso E., et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: A systematic review and meta-analysis // Br J Dermatol. 2016. Vol. 175, N 6. P. 1153–1165. doi: 10.1111/bjd.14768</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Wang L, Ke X, Kavati A, et al. Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria. Curr Med Res Opin. 2018;34(1):35–39. doi: 10.1080/03007995.2017.1395732</mixed-citation><mixed-citation xml:lang="ru">Wang L., Ke X., Kavati A., et al. Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria // Curr Med Res Opin. 2018. Vol. 34, N 1. P. 35–39. doi: 10.1080/03007995.2017.1395732</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742–1750.e4. doi: 10.1016/j.jaci.2015.12.1342</mixed-citation><mixed-citation xml:lang="ru">Zhao Z.T., Ji C.M., Yu W.J., et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials // J Allergy Clin Immunol. 2016. Vol. 137, N 6. P. 1742–1750.e4. doi: 10.1016/j.jaci.2015.12.1342</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: A meta-analysis of "real-world" evidence. JAMA Dermatol. 2019;155(1):29–38. doi: 10.1001/jamadermatol.2018.3447</mixed-citation><mixed-citation xml:lang="ru">Tharp M.D., Bernstein J.A., Kavati A., et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: A meta-analysis of "real-world" evidence // JAMA Dermatol. 2019. Vol. 155, N 1. P. 29–38. doi: 10.1001/jamadermatol.2018.3447</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Fok JS, Kolkhir P, Church MK, Maurer M. Predictors of treatment response in chronic spontaneous urticaria. Allergy. 2021;76(10):2965–2981. doi: 10.1111/all.14757</mixed-citation><mixed-citation xml:lang="ru">Fok J.S., Kolkhir P., Church M.K., Maurer M. Predictors of treatment response in chronic spontaneous urticaria // Allergy. 2021. Vol. 76, N 10. P. 2965–2981. doi: 10.1111/all.14757</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Curto-Barredo L, Archilla LR, Vives GR, et al. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment. Acta Derm Venereol. 2018;98(7):641–647. doi: 10.2340/00015555-2941</mixed-citation><mixed-citation xml:lang="ru">Curto-Barredo L., Archilla L.R., Vives G.R., et al. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment // Acta Derm Venereol. 2018. Vol. 98, N 7. P. 641–647. doi: 10.2340/00015555-2941</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Maurer M, Staubach P, Raap U, et al. H1-antihistamine-refractory chronic spontaneous urticaria: It's worse than we thought: First results of the multicenter real-life AWARE study. Clin Exp Allergy. 2017;47(5):684–692. doi: 10.1111/cea.12900</mixed-citation><mixed-citation xml:lang="ru">Maurer M., Staubach P., Raap U., et al. H1-antihistamine-refractory chronic spontaneous urticaria: It's worse than we thought: First results of the multicenter real-life AWARE study // Clin Exp Allergy. 2017. Vol. 47, N 5. P. 684–692. doi: 10.1111/cea.12900</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Trinh HK, Pham DL, Ban GY, et al. Altered systemic adipokines in patients with chronic urticaria. Int Arch Allergy Immunol. 2016;171(2):102–110. doi: 10.1159/000452626</mixed-citation><mixed-citation xml:lang="ru">Trinh H.K., Pham D.L., Ban G.Y., et al. Altered systemic adipokines in patients with chronic urticaria // Int Arch Allergy Immunol. 2016. Vol. 171, N 2. P. 102–110. doi: 10.1159/000452626</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Kolkhir P, Pogorelov D, Olisova O. CRP, D-dimer, fibrinogen and ESR as predictive markers of response to standard doses of levocetirizine in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol. 2017;49(4):189–192. doi: 10.23822/eurannaci.1764-1489.05</mixed-citation><mixed-citation xml:lang="ru">Kolkhir P., Pogorelov D., Olisova O. CRP, D-dimer, fibrinogen and ESR as predictive markers of response to standard doses of levocetirizine in patients with chronic spontaneous urticaria // Eur Ann Allergy Clin Immunol. 2017. Vol. 49, N 4. P. 189–192. doi: 10.23822/eurannaci.1764-1489.05</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Sánchez Borges M, Tassinari S, Flores A. [Epidemiologic features in patients with antihistamine-resistant chronic urticaria. (In Spanish)]. Rev Alerg Mex. 2015;62(4):279–286.</mixed-citation><mixed-citation xml:lang="ru">Sánchez Borges M., Tassinari S., Flores A. [Epidemiologic features in patients with antihistamine-resistant chronic urticaria. (In Spanish)] // Rev Alerg Mex. 2015. Vol. 62, N 4. P. 279–286.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Danilycheva I, Emelyanov A, Meshkova R, et al. Treating chronic urticaria refractory to H1-antihistamines in Russia: Data from the AWARE study. Postepy Dermatol Alergol. 2022;39(3):509–516. doi: 10.5114/ada.2022.117556</mixed-citation><mixed-citation xml:lang="ru">Danilycheva I., Emelyanov A., Meshkova R., et al. Treating chronic urticaria refractory to H1-antihistamines in Russia: Data from the AWARE study // Postepy Dermatol Alergol. 2022. Vol. 39, N 3. P. 509–516. doi: 10.5114/ada.2022.117556</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Ye YM, Jin HJ, Hwang EK, et al. Co-existence of chronic urticaria and metabolic syndrome: Clinical implications. Acta Derm Venereol. 2013;93(2):156–160. doi: 10.2340/00015555-1443</mixed-citation><mixed-citation xml:lang="ru">Ye Y.M., Jin H.J., Hwang E.K., et al. Co-existence of chronic urticaria and metabolic syndrome: Clinical implications // Acta Derm Venereol. 2013. Vol. 93, N 2. P. 156–160. doi: 10.2340/00015555-1443</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Zbiciak-Nylec M, Wcisło-Dziadecka D, Kasprzyk M, et al. Overweight and obesity may play a role in the pathogenesis of chronic spontaneous urticaria. Clin Exp Dermatol. 2018;43(5):525–528. doi: 10.1111/ced.13368</mixed-citation><mixed-citation xml:lang="ru">Zbiciak-Nylec M., Wcisło-Dziadecka D., Kasprzyk M., et al. Overweight and obesity may play a role in the pathogenesis of chronic spontaneous urticaria // Clin Exp Dermatol. 2018. Vol. 43, N 5. P. 525–528. doi: 10.1111/ced.13368</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Lapi F, Cassano N, Pegoraro V, et al. Epidemiology of chronic spontaneous urticaria: Results from a nationwide, population-based study in Italy. Br J Dermatol. 2016;174(5):996–1004. doi: 10.1111/bjd.14470</mixed-citation><mixed-citation xml:lang="ru">Lapi F., Cassano N., Pegoraro V., et al. Epidemiology of chronic spontaneous urticaria: Results from a nationwide, population-based study in Italy // Br J Dermatol. 2016. Vol. 174, N 5. P. 996–1004. doi: 10.1111/bjd.14470</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Soria A, Du-Thanh A, Amsler E, et al.; French urticaria group (GUS) of French dermatological society. Obesity is not associated with severe chronic urticaria in a French cohort. J Eur Acad Dermatol Venereol. 2018;32(6):e247–e249. doi: 10.1111/jdv.14767</mixed-citation><mixed-citation xml:lang="ru">Soria A., Du-Thanh A., Amsler E., et al.; French urticaria group (GUS) of French dermatological society. Obesity is not associated with severe chronic urticaria in a French cohort // J Eur Acad Dermatol Venereol. 2018. Vol. 32, N 6. P. e247–e249. doi: 10.1111/jdv.14767</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: An appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am. 2004;33(2):431–453. doi: 10.1016/j.ecl.2004.03.008</mixed-citation><mixed-citation xml:lang="ru">Devaraj S., Rosenson R.S., Jialal I. Metabolic syndrome: An appraisal of the pro-inflammatory and procoagulant status // Endocrinol Metab Clin North Am. 2004. Vol. 33, N 2. P. 431–453. doi: 10.1016/j.ecl.2004.03.008</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Neiman M, Hellström C, Just D, et al. Individual and stable autoantibody repertoires in healthy individuals. Autoimmunity. 2019;52(1):1–11. doi: 10.1080/08916934.2019.1581774</mixed-citation><mixed-citation xml:lang="ru">Neiman M., Hellström C., Just D., et al. Individual and stable autoantibody repertoires in healthy individuals // Autoimmunity. 2019. Vol. 52, N 1. P. 1–11. doi: 10.1080/08916934.2019.1581774</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Tsigalou C, Vallianou N, Dalamaga M. Autoantibody production in obesity: Is there evidence for a link between obesity and autoimmunity? Curr Obes Rep. 2020;9(3):245–254. doi: 10.1007/s13679-020-00397-8</mixed-citation><mixed-citation xml:lang="ru">Tsigalou C., Vallianou N., Dalamaga M. Autoantibody production in obesity: Is there evidence for a link between obesity and autoimmunity? // Curr Obes Rep. 2020. Vol. 9, N 3. P. 245–254. doi: 10.1007/s13679-020-00397-8</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Asero R, Cugno M. Biomarkers of chronic spontaneous urticaria and their clinical implications. Expert Rev Clin Immunol. 2021;17(3):247–254. doi: 10.1080/1744666X.2021.1882304</mixed-citation><mixed-citation xml:lang="ru">Asero R., Cugno M. Biomarkers of chronic spontaneous urticaria and their clinical implications // Expert Rev Clin Immunol. 2021. Vol. 17, N 3. P. 247–254. doi: 10.1080/1744666X.2021.1882304</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Fang X, Li M, He C, et al. Plasma-Derived exosomes in chronic spontaneous urticaria induce the production of mediators by human mast cells. J Invest Dermatol. 2022;142(11):2998–3008.e5. doi: 10.1016/j.jid.2022.03.037</mixed-citation><mixed-citation xml:lang="ru">Fang X., Li M., He C., et al. Plasma-Derived exosomes in chronic spontaneous urticaria induce the production of mediators by human mast cells // J Invest Dermatol. 2022. Vol. 142, N 11. P. 2998–3008.e5. doi: 10.1016/j.jid.2022.03.037</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Razina AO, Runenko SD, Achkasov EE. Obesity: Current global and Russian trends. Annals Russ Academ Med Scis. 2016;71(2):154–159. (In Russ). doi: 10.15690/vramn655</mixed-citation><mixed-citation xml:lang="ru">Разина А.О., Руненко С.Д., Ачкасов Е.Е. Проблема ожирения: современные тенденции в России и в мире // Вестник Росс. акад. мед. наук. 2016. Т. 71, № 2. С. 154–159. doi: 10.15690/vramn655</mixed-citation></citation-alternatives></ref></ref-list></back></article>
